Back to search results

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Herpes Zoster

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • National Institutes of Health Clinical Center, Bethesda, Maryland, United States

    Contact: Study coordinator (For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · ccopr@nih.gov · 800-411-1222
Study leads

  • Maura M Manion, M.D.

    Principal Investigator

    National Institute of Allergy and Infectious Diseases (NIAID)

View source on ClinicalTrials.gov(opens in a new tab)